What Elastic NV ESTC is building for next year Q1 2026 EPS Beats Forecasts Regeneron Pharmaceuticals REGN Otarmeni Gene Therapy Launch Shifts LongTerm Narrative Amid Pipeline Execution Focus CGC CanopyGrowth falls 522 after Q1 2026 EPS dramatically misses estimates with no reported revenue data The valuation case for Accelerant ARX that is hard to ignore Gathers Momentum 20260508